Welgene Biotech Co., Ltd. AI Stock Analysis
Welgene Biotech Co., Ltd. (6661) AI Stock Analysis
Welgene Biotech Co., Ltd.
(TPEx:6661)
The overall score of 38 is deeply bearish, driven primarily by a severe deterioration in financial performance. The company's inability to generate profit or positive free cash flow, coupled with a sharp increase in debt, presents a high-risk profile. This is compounded by a weak technical trend with the stock trading below all major moving averages and a negative P/E ratio that underscores the lack of earnings. The company is in a precarious financial position with no positive catalysts from valuation or market momentum.
Welgene Biotech Co., Ltd. (6661) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- TWD 344.90M
- Dividend Yield
- ―
- Average Volume (3M)
- 5,499
- Price to Earnings (P/E)
- -30.5
- Beta (1Y)
- 0.23
- Revenue Growth
- 6.57%
- EPS Growth
- -822.48%
- Country
- TW
- Employees
- 80
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Welgene Biotech Co., Ltd. Business Overview & Revenue Model
Company Description
Welgene Biotech Co.,Ltd. primarily focuses on delivering genetic analysis services. The company provides comprehensive support for scientific research, employing a range of advanced laboratory techniques such as genetic sequencing, microarray analysi...
Welgene Biotech Co., Ltd. Financial Statement Overview
Summary
Financial health is critically weak. The Income Statement (Score 28) shows collapsing profitability with a net margin of just 0.4% and eroding gross margins. The Cash Flow Statement (Score 18) is alarming, with negative free cash flow of -NT$6.1M, indicating the company cannot fund its investments internally. The Balance Sheet (Score 42) shows a concerning spike in debt-to-equity from 0.17 to 0.80, increasing financial risk. The overall trend is a severe deterioration in profitability and cash generation, funded by aggressive leveraging.
Income Statement
28NegativeBalance Sheet
42NeutralCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 398.92M | 375.94M | 322.55M | 280.55M | 321.90M | 312.65M |
| Gross Profit | 144.89M | 129.27M | 135.84M | 119.72M | 141.80M | 133.27M |
| EBITDA | 30.93M | 27.92M | 33.01M | 26.84M | 35.66M | 39.12M |
| Net Income | -1.64M | 1.33M | 1.11M | -2.65M | 9.55M | 13.70M |
Balance Sheet | ||||||
| Total Assets | 658.59M | 622.19M | 528.25M | 548.16M | 435.71M | 424.54M |
| Cash, Cash Equivalents and Short-Term Investments | 201.99M | 269.03M | 228.19M | 197.83M | 218.36M | 224.26M |
| Total Debt | 281.15M | 226.03M | 129.83M | 154.35M | 51.19M | 23.84M |
| Total Liabilities | 380.96M | 336.12M | 232.50M | 247.89M | 131.76M | 114.47M |
| Stockholders Equity | 273.14M | 281.30M | 287.91M | 292.03M | 303.76M | 309.86M |
Cash Flow | ||||||
| Free Cash Flow | -102.42M | -6.08M | 51.27M | -28.10M | 24.57M | 6.87M |
| Operating Cash Flow | 29.09M | 35.27M | 56.08M | -366.00K | 51.43M | 11.25M |
| Investing Cash Flow | -127.35M | -35.74M | -45.19M | 6.00M | -67.99M | -10.34M |
| Financing Cash Flow | 85.35M | 51.31M | -25.52M | 23.91M | -24.61M | 38.52M |
Welgene Biotech Co., Ltd. Peers Comparison
Overall Rating
TW:418354Neutral
TW:666138Underperform
Financial Indicators
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TW:6661 | Welgene Biotech Co., Ltd. | 15.15 | -3.75 | -19.84% | |
| TW:4117 | General Biologicals Corp. | 7.48 | -4.37 | -36.88% | |
| TW:4183 | EPS Bio Technology Corp. | 14.50 | -2.55 | -14.96% | |
| TW:6660 | HMD Biomedical, Inc. | 10.40 | -13.35 | -56.21% | |
| TW:6848 | RBC Bioscience Corporation | 20.35 | 6.44 | 46.26% | |
| TW:7595 | Pharmigene, Inc. | 8.98 | -2.32 | -20.53% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 10, 2026
